TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15100715
Drug: High-protein, high-sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein, high-sodium diet (90 g protein/day, 180 mmol sodium/day)
Study: 15100715
Drug: Moderate-protein, low-sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-protein, low-sodium diet (70 g protein/day, 65 mmol sodium/day)
Study: 8348277
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg of i.m. depot methylprednisolone acetate (MPA)
Study: 8348277
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg methylprednisolone (MP) orally
Study: 2883004
Drug: Acellular pertussis
Normalized name: Acellular pertussis vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular pertussis vaccine JNIH‐6
Study: 2883004
Drug: Placebo (carrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (carrier solution of aluminium phosphate)
Study: 29751193
Drug: High added
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High added sugar low fiber diet (HASLF; 25% total energy from AS and 8.2 g/1000 kcal)
Study: 20417426
Drug: Conventional hysteroscopy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional hysteroscopy with saline solution
Study: 12872556
Drug: Mupirocin treatment
Normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mupirocin treatment (n = 96)
Study: 8537688
Drug: Pyrimethamine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrimethamine (50 mg) with folinic acid (15 mg) given three times weekly
Study: 1907074
Drug: Thyrotropin-releasing hormone
Normalized name: thyrotropin-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyrotropin-releasing hormone (200 micrograms intravenous)
Study: 1907074
Drug: Thyrotropin-releasing hormone
Normalized name: thyrotropin-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyrotropin-releasing hormone (400 micrograms intravenous)
Study: 9290464
Drug: Thyrotropin-releasing hormone
Normalized name: thyrotropin-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyrotropin-releasing hormone
Study: 7051244
Drug: Trimethoprim (TMP)
Normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trimethoprim (TMP) 320 mg plus Sulfamethoxazole (SMZ) 1,600 mg daily for 14 days
Study: 7051244
Drug: Ampicillin 2
Normalized name: ampicillin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin 2 g daily for 14 days
Study: 30496879
Drug: Dose differences
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose differences between dCT and CT treatment plans
Study: 21417591
Drug: Air-abrasive treatment
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air-abrasive treatment
Study: 1965344
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no calcium entry blocker)
Study: 20605604
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg of ropivacaine (group I)
Study: 2977392
Drug: Acitretin administered
Normalized name: Acitretin
DrugBank: Acitretin (DB00459)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acitretin administered with food (moderate breakfast)
Study: 2977392
Drug: Acitretin administered
Normalized name: Acitretin
DrugBank: Acitretin (DB00459)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acitretin administered during a complete fast
Study: 23540442
Drug: CsA 5
Normalized name: CsA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA 5 mg/kg continuous infusion over 24 hours
Study: 14595084
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of OROS methylphenidate HCL (MPH)
Study: 10898926
Drug: Bromperidol at
Normalized name: bromperidol
DrugBank: Bromperidol (DB12401)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromperidol at 6 or 12 or 18 mg/day for 3 weeks
Study: 6611585
Drug: Urea (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urea (1.0 g/kg b.w.)
Study: 26362090
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (RT) with short-course androgen deprivation therapy (ADT) (4 months of GnRH agonist therapy and antiandrogen)
Study: 8311085
Drug: Low-dose cyclosporine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cyclosporine (≤5 mg/kg/d)
Study: 8311085
Drug: Second biopsy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second biopsy after further 18 months of therapy
Study: 3582481
Drug: Ranitidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (300 mg o.d.)
Study: 31648099
Drug: Patritumab +
Normalized name: Patritumab
DrugBank: Patritumab (DB12090)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patritumab + cetuximab + platinum therapy
Study: 31648099
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + cetuximab + platinum therapy
Study: 28950289
Drug: Glycoengineered imgatuzumab
Normalized name: Imgatuzumab
DrugBank: Imgatuzumab (DB14884)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycoengineered imgatuzumab (GA201; 700 mg)
Study: 28950289
Drug: Both antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both antibodies
Study: 23883812
Drug: Pollen blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pollen blocker cream applied three times daily for 30 days
Study: 22796122
Drug: Plant sterol/stanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant sterol/stanol softgel capsules (1.8 g/d)
Study: 10877012
Drug: Rofecoxib 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib 100 mg
Study: 9126665
Drug: Testosterone-enanthate (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone-enanthate (200 mg/week intramuscularly)
Study: 9126665
Drug: Testolactone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testolactone (1 g/day orally)
Study: 9126665
Drug: Testosterone-enanthate (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone-enanthate (200 mg/week) + Testolactone (1 g/day)
Study: 8243792
Drug: 10 mg/day
Normalized name: Adlarity 10 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day cyclobenzaprine at bedtime
Study: 31923712
Drug: Whole Pelvic
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole Pelvic Radiation Therapy (WPRT)
Study: 20678219
Drug: Individual written
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual written prescription for exercise (Control)
Study: 2418400
Drug: 5‐fluorouracil (B‐CMF)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐fluorouracil (B‐CMF) chemotherapy prior to and two courses after standard therapy
Study: 2418400
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (preoperative irradiation followed by radical surgery)
Study: 27310254
Drug: 450 mg
Normalized name: aspirin 450 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 mg daily valganciclovir (group 1)
Study: 27310254
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg daily valganciclovir (group 2)
Study: 22594981
Drug: Topical photodynamic
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical photodynamic therapy using methylene blue and Hypericum perforatum extract
Study: 15832335
Drug: High exposure
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High exposure condition (0.63 W/kg 1 g averaged SAR)
Study: 12887472
Drug: Triptorelin 3.75
Normalized name: triptorelin 3.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin 3.75 mg
Study: 19035858
Drug: Leuprolide 7.5
Normalized name: leuprolide 7.5 mg/month intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide 7.5 mg
Study: 7201905
Drug: Cisplatin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (60 mg/m2 IV) administered in the morning (6:00 A.M.)
Study: 30635477
Drug: Placebo induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo induction followed by glatiramer acetate (GA) monotherapy
Study: 28835387
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D and leucine-enriched whey protein medical nutrition drink (21 g leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D3)
Study: 19507458
Drug: Intravenous zoledronic
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous zoledronic acid (ZO group)
Study: 12456630
Drug: Continuous oral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous oral estrogen/progestin (n = 21)
Study: 12456630
Drug: Continuous oral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous oral estrogen/intrauterine progestin (n = 22)
Study: 1973085
Drug: Bromocriptine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (5 mg divided daily)
Study: 1973085
Drug: Bromocriptine (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (5-10 mg)
Study: 7213506
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily dosage (0.25 mg)
Study: 7213506
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily dosage (0.125 mg)
Study: 7213506
Drug: Four times
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four times daily dosage (0.0625 mg)
Study: 7213506
Drug: All dosage
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All dosage frequencies
Study: 31182128
Drug: Med-Stress intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Med-Stress intervention (sequential enhancement of self-efficacy and perceived social support)
Study: 31182128
Drug: Med-Stress intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Med-Stress intervention (sequential enhancement of perceived social support and self-efficacy)
Study: 25841539
Drug: Synbiotic yogurt
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic yogurt (containing Streptococcus thermophilus, Lactobacillus bulgaricus, Bifidobacterium animalis subspecies lactis (BB‐12) at 5 × 10(9) cfu/100 mL and 1 g of inulin)
Study: 19741531
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin noradrenaline reuptake inhibitors
Study: 6537445
Drug: Drug education
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug education course
Study: 30639756
Drug: Factors evaluated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Factors evaluated included age, sex, diagnosis, morning/evening assessment, modified Medical Research Council breathlessness score, morphine treatment
Study: 11129615
Drug: Epidural PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural PCA with bupivacaine 0.125%, sufentanil 0.75 microgram/ml and epinephrine 1/800.000 with a basal rate of 3 ml/hr
Study: 8750479
Drug: New anticancer
Approvals — FDA: no, EMA: no, PMDA: no
Description: New anticancer therapies
Study: 1724541
Drug: Low-rate ANF
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-rate ANF infusion (0.25 micrograms/min)
Study: 477026
Drug: Intramuscular immune
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular immune serum globulin (ISG)
Study: 477026
Drug: Intravenous modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous modified immune serum globulin (M‐ISG)
Study: 25562479
Drug: Daily disposable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily disposable contact lenses (nelfilcon A, DAILIES AquaComfort Plus)
Study: 20926751
Drug: Tonapofylline (0.2-375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tonapofylline (0.2-375 mg)
Study: 20926751
Drug: Tonapofylline (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tonapofylline (single dose)
Study: 17681360
Drug: GPO dihydroartemisinin
Normalized name: .alpha.-dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: GPO dihydroartemisinin tablet formulation, 200mg single oral dose
Study: 17681360
Drug: Dafra dihydroartemisinin
Normalized name: .alpha.-dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dafra dihydroartemisinin tablet formulation, 200mg single oral dose
Study: 17681360
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of DHA (both formulations)
Study: 17681360
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of DHA (both formulations)
Study: 16649968
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (1 mg/kg i.m. every 4 weeks for 6 months) + Letrozole (2.5 mg/day orally for 12 months)
Study: 16649968
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (1 mg/kg i.m. every 4 weeks for 6 months) + Placebo
Study: 12562453
Drug: Omeprazole, 20
Normalized name: Omeprazole, 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole, 20 mg/day for 5 days with 3 mg budesonide controlled-release capsules on day 5
Study: 2130823
Drug: Usual diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual diet (438 +/- 118 mg/day)
Study: 28648880
Drug: Animated biofeedback
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Animated biofeedback therapy
Study: 28648880
Drug: Non-animated biofeedback
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-animated biofeedback therapy
Study: 20526200
Drug: No use
Approvals — FDA: no, EMA: no, PMDA: no
Description: No use of hormone therapy
Study: 16104901
Drug: DN-101 (high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: DN-101 (high-dose oral calcitriol) combined with docetaxel
Study: 10368039
Drug: Oxygen inhalation
Normalized name: oxygen INHALATION GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen inhalation during radiotherapy sessions
Study: 10368039
Drug: Oxygen inhalation
Normalized name: oxygen INHALATION GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen inhalation during all radiotherapy sessions
Study: 6109345
Drug: Tofisopam (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofisopam (100 mg single dose)
Study: 6109345
Drug: Diazepam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (10 mg single dose)
Study: 6109345
Drug: Diazepam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (10 mg) + Ethanol (0.8 g/kg)
Study: 6109345
Drug: Tofisopam (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofisopam (100 + 50 + 50 + 100 mg repeated doses)
Study: 27445468
Drug: UMEC/VI 62.5/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: UMEC/VI 62.5/25 µg
Study: 8183178
Drug: Nasal salmon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal salmon calcitonin (SCT) (100 IU daily) plus oral calcium
Study: 3963018
Drug: Flurbiprofen (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen (200 mg total daily dose, administered four times a day)
Study: 3963018
Drug: Flurbiprofen (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen (up to 300 mg per day)
Study: 31137095
Drug: Group B1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B1 (sound therapy for normal to mild hearing loss)
Study: 31137095
Drug: Group A2
Normalized name: PROCYANIDIN A2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A2 (sound therapy for moderate to profound hearing loss)
Study: 27895466
Drug: CKD‐519 (25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CKD‐519 (25, 50, 100, 200, or 400 mg)
Study: 15838760
Drug: Oral Sialogogum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Sialogogum
Study: 28432193
Drug: Antimicrobial (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial (6 mg/kg gamithromycin)
Study: 23505169
Drug: 3 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/day of IQP G‐002AS
Study: 14503053
Drug: TCM group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCM group (Chinese drug medication according to patients' syndrome differentiation)
Study: 11768164
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg DHA
Study: 11768164
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg DHA
Study: 2962589
Drug: Phosphonoformate (PFA)
Normalized name: Phosphonoformic acid
DrugBank: Foscarnet (DB00529)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Phosphonoformate (PFA) intravenous infusion
Study: 26149448
Drug: Oral Chinese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Chinese herbal formula (Pei Tu Qing Xin granules; PTQX)
Study: 21677054
Drug: Lactating women
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactating women receiving no protein-energy supplements (control group for protein-energy trial)
Study: 11182048
Drug: alphaD3 (1alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: alphaD3 (1alpha (OH) D3) administered to 18 patients
Study: 9297265
Drug: Transdermal nitroglycerine
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerine (Nitroderm NNS 5)
Study: 28275100
Drug: Small-Quantity Lipid-Based
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small-Quantity Lipid-Based Nutrient Supplements (SQ-LNSs; 20 g with 22 micronutrients/d)
Study: 28275100
Drug: Iron and
Normalized name: beef,iron and wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron and Folic Acid (IFA; 60 mg Fe + 400 μg folic acid/d)
Study: 28275100
Drug: Control (Placebo;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Placebo; 200 mg Ca/d)
Study: 19276255
Drug: Weekly bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly bolus irinotecan, 5-fluorouracil, and leucovorin (IFL)
Study: 19276255
Drug: Weekly bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly bolus 5-fluorouracil/leucovorin
Study: 11306209
Drug: 17beta-estradiol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17beta-estradiol (1 mg/day) combined with dydrogesterone (5, 10 or 20 mg/day)
Study: 2648510
Drug: Regime A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regime A: Rifampicin, Isoniazid, Streptomycin, Pyrazinamide for 2 months followed by Rifampicin and Isoniazid for 4 months (total 6 months treatment)
Study: 31065839
Drug: Information booklet
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Information booklet about prostate cancer treatment options prior to biopsy
Study: 19415543
Drug: Parathyroid hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parathyroid hormone (PTH); specific dosage and duration not mentioned.
Study: 11336078
Drug: Pilocarpine 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilocarpine 5.0 mg (1 cc) tid at meal times during radiation
Study: 9130837
Drug: Long-term medication
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term medication
Study: 7573830
Drug: loratadine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: loratadine (20 mg/day orally)
Study: 25923680
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment with intraforaminal injection of steroid and anaesthetic
Study: 20089783
Drug: Virgin Olive
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virgin Olive Oil (VOO) - 629 mg/L phenol concentration
Study: 20089783
Drug: Refined Olive
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refined Olive Oil (ROO) - 0 mg/L phenol concentration
Study: 15853207
Drug: Drugs other
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs other than nitrosourea or drugs that reduce MGMT activity
Study: 15853207
Drug: Targeting growth
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeting growth factor receptors such as EGFR or VEGFR
Study: 8656422
Drug: Testosterone 2%
Normalized name: TESTOSTERONE 2% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone 2% ointment
Study: 8656422
Drug: Placebo cream-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream-based preparation
Study: 1503133
Drug: Day treatment
Normalized name: Pharmacist Clotrimazole 3 Day Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day treatment (experimental condition)
Study: 6337763
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal (140 gm) in divided doses over 12 hr
Study: 6697647
Drug: Repeated oral
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated oral doses of activated charcoal
Study: 18854201
Drug: Bolus isoproterenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus isoproterenol infusions
Study: 16874208
Drug: Vacuum-assisted closure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vacuum-assisted closure therapy
Study: 14974959
Drug: Conventional moist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional moist gauze therapy
Study: 11166898
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of 90 microg rH5 vaccine
Study: 29653390
Drug: Fondaparinux 2.5
Normalized name: FONDAPARINUX 2.5MG/0.5ML INJ SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fondaparinux 2.5 mg daily (Group F)
Study: 25302236
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol (75 patients)